ARCHIVES

Trial Data: No Benefit In Adding Perifosine to Capecitabine

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

May 30, 2014

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008

Give New Investigators “Special Consideration,” Advisors Tell NCI

June 28, 2002

Study Tests PARP Inhibitor ABT-888 For Several Cancers

September 25, 2009

Breast Cancer Incidence Goes Up, Most of it in Early, Local Stages

July 11, 1988

Sexual Function Affected By Stem Cell Transplant

September 28, 2007